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Concurrent OX40 and CD30 Ligand Blockade Abrogates the
CD4-Driven Autoimmunity Associated with CTLA4 and
PD1 Blockade while Preserving Excellent Anti-CD8
Tumor Immunity
Maher G. Nawaf,*,† Maria H. Ulvmar,‡ David R. Withers,*,† Fiona M. McConnell,*,†
Fabrina M. Gaspal,*,† Gwilym J. Webb,*,† Nick D. Jones,*,† Hideo Yagita,x
James P. Allison,{ and Peter J. L. Lane*,†
Although strategies that block FOXP3-dependent regulatory T cell function (CTLA4 blockade) and the inhibitory receptor PD1
have shown great promise in promoting antitumor immune responses in humans, their widespread implementation for cancer
immunotherapy has been hampered by significant off-target autoimmune side effects that can be lethal. Our work has shown that
absence of OX40 and CD30 costimulatory signals prevents CD4 T cell–driven autoimmunity in Foxp3-deficient mice, suggesting a
novel way to block these side effects. In this study, we show that excellent antitumor CD8 T cell responses can be achieved in
Foxp3KO mice deficient in OX40 and CD30 signals, particularly in the presence of concurrent PD1 blockade. Furthermore,
excellent antitumor immune responses can also be achieved using combinations of Abs that block CTLA4, PD1, OX40, and
CD30 ligands, without CD4 T cell–driven autoimmunity. By dissociating autoimmune side effects from anticancer immune
responses, this potentially shifts this antitumor approach to patients with far less advanced disease. The Journal of Immunology,
2017, 199: 974–981.
M
anyhuman cancers are characterized by tumor-infiltrating
lymphocytes that include CD4 and CD8 T cells, indi-
cating that tumors do evoke an immune response,
probably due to the numerous mutant proteins expressed in can-
cerous cells (1, 2). However, two well-characterized mechanisms
exist to protect tumors from attack by the host immune system.
Foxp3-dependent regulatory T cells (Tregs), specific for self-antigens
expressed in medullary thymic epithelium (3, 4), can dominantly
negatively regulate CD4 and CD8 anticancer responses. Second, in
addition to Tregs, many tumors also express the inhibitory ligand
PDL1, which can directly inhibit tumor-infiltrating PD1-expressing
CD8 T cells from killing their tumor targets.
To counter these inhibitory pathways that prevent effective anti-
tumor immunity, therapies have been developed in humans to block
Treg function. The main effector pathway by which Tregs work is
through expression of CTLA4 (5), and CTLA4 blockade (6) and PD1
blockade (7) have been shown to be efficacious in some patients with
melanoma, particularly when used in combination (8, 9), with 61% of
patients in the latter study getting a clinically relevant responses.
However, these studies also highlighted dose-dependent toxicity as-
sociated with autoimmunity and correlated with efficacy. Toxicity led
to grade 3 (requiring hospitalization) and grade 4 (life-threatening)
side effects in 54% of treated patients and limited the extent to which
dosage could be escalated. The lethal CD4-driven autoimmunity seen
in CTLA4-deficient mice (10) shows that at best CTLA4 blockade
must be incomplete in human cancer immunotherapy, and although
the autoimmunity associated with PD1 deficiency is relatively mild
(11), the human melanoma studies show that the autoimmunity
is augmented by blocking both CTLA4 and PD1 pathways. The
mechanism by which CTLA4-blocking Abs works is controversial.
Some studies in humans and mice have demonstrated that they de-
plete intratumoral Tregs via Fc receptor–mediated mechanisms (12–
14) rather than only working by blocking CTLA4. Indeed, depletion
of Tregs in adult mice is associated with rapid-onset autoimmunity
(15), which might explain at least some of the effects for the off-
target autoimmunity observed with CTLA4-blocking Abs. The story
with adult CTLA4 depletion is contentious, with studies showing
mild (16) to quite severe autoimmunity (17) in mice. However, note
that in humans, haploinsufficiency of CTLA4 is associated with
significant autoimmunity (18, 19), so blockade of CTLA4 could act
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synergistically with Treg depletion to promote the CD4-driven au-
toimmunity seen in mice and humans lacking Tregs (20, 21). We
have previously shown that the CD4-driven fatal autoimmunity seen
in Foxp3-deficient mice is abrogated in the absence of OX40 and
CD30, whereas CD8 immunity was preserved. This raised the pos-
sibility that blocking OX40 and CD30 signaling could attenuate
CD4-driven autoimmunity without compromising CD8 antitumor
responses.
Materials and Methods
Mice
For tumor experiments, wild-type (C57BL/6, Charles River Laboratories),
CD30KO OX40KO (double knockout [dKO], C57BL/6), and CD30KO
OX40KO Foxp3KO (triple knockout [tKO], C57BL/6) female mice (6–8
wk old) were bred and maintained in the animal facilities at the Bio-
medical Services Unit (University of Birmingham, U.K.). The dKO and
tKO mice were generated as described previously (22, 23). In experi-
ments where mAbs were injected, female C57BL/6 mice were used for
experiments.
Murine cell culture and preservation
The murine melanoma B16-F10 cell line (24) was obtained from American
Type Culture Collection and has not since been tested for mycobacterial
contamination. This cell line is not on the International Cell Line Au-
thentication Committee database of commonly misidentified cell lines. It
was cultured in T75 vent cap tissue culture flasks (Sarstedt) using 15 ml of
13 DMEM (Life Technologies) supplemented with 10% heat-inactivated
FBS (Sigma-Aldrich) and 100 IU/ml Penicillin, 100 mg/ml Streptomycin
(Life Technologies). The cells were harvested in log phase of their growth
before injection into mice.
Subcutaneous injection of mice
Female mice aged 6–8 wk were used for the tumor melanoma model.
When possible, age-matched littermates were used, and mice were allo-
cated randomly to treatment groups. B16-F10 melanoma cell suspension
was prepared as described above. Mice were anesthetized and the right
dorsal flank areas were shaved and treated with disinfectant, prior to s.c.
injection of 500,000 B16-F10 cells resuspended in 100 ml of PBS into the
right dorsal flank. Tumor growth was measured biweekly using calipers.
The mouse body weight was monitored and tumor volumes were calcu-
lated using the equation V = p/6 3 l 3 d2, where V indicates volume, l
refers to the long diameter, and d is the short diameter. Mice were sacri-
ficed when the tumor size was .12.5 mm in diameter.
Preparation of cell suspensions for flow cytometry
Tumors were weighed after excision. Single-cell suspensions were pre-
pared from tumors, spleen, and draining and nondraining inguinal lymph
nodes. Tumors and lymph nodes were cut into small pieces and then
digested in 1 ml of digestion medium composed of RPMI 1640, 2% FCS,
100 mg/ml DNase (Roche Applied Science), and 1 mg/ml collagenase
D (Roche Applied Science) at 37˚C for 30 min. Splenocytes were
prepared by physical disaggregation with filtering through a strainer
followed by lysis in Gey’s solution. To reduce cell clumping, 1 mM/ml
EDTA (Sigma-Aldrich) was added to the digested suspension, which
was then filtered through a 70-mm cell strainer (Falcon). Cells were
then resuspended in 800 ml of RPMI 1640 for tumors and 400 ml for lymph
nodes.
Flow cytometric analysis
Ninety-six–well rounded-bottom plates (Serilin) were seeded with
200 ml of the cell suspensions, centrifuged at 4˚C, 1400 rpm for 3 min,
and then washed with cold PBS before staining. The washed cells
were first surface stained with Live/Dead near-IR dye (Molecular
Probes) for 20 min on ice to separate viable and nonviable cells. The
following mAbs were used in this study: anti-CD45 (eBioscience),
anti-CD3 PE (clone 500A2; eBioscience), anti-CD4 V500 (clone
RM4-5; BD Biosciences), anti-CD8 eFluor 450 (clone 53-6.7; eBio-
science), anti-CD25 allophycocyanin (clone PC61; eBioscience), anti-
CD44 PE-Cy7 (clone IM7; eBioscience), anti-Foxp3 FITC (clone FJK-16s;
eBioscience), anti-PD1 PE-Cy7 (clone RMP1-30; BioLegend, U.K.), anti–
granzyme B FITC (clone GB11; BioLegend), ant–IFN-g PE-Cy7 (clone
XMG1.2; eBioscience), and anti-CTLA4 PE-Cy7 (clone UC10-4B9;
BioLegend).
Intracellular staining for Foxp3 and CTLA4 was performed following
surface staining, fixation, and permeabilization of the cells with a Foxp3
fixation/permeabilization kit (eBioscience). Anti-CD3–coated plates plus
CD28 were used to investigate IFN-g production after a total of 4 h of
incubation at 37˚C using GolgiStop (BD Biosciences) and a Cytofix/
Cytoperm Plus (BD Biosciences) kit. The cells were washed twice and
resuspended in 200 ml of FACS buffer (0.1% FBS in PBS). Ten microliters
of counting beads (10,000/10 ml) (Spherotech) was added to each sample
before analysis according to the manufacturer’s protocol. A Beckman
Coulter CyAn ADP was used for acquiring the samples, and FlowJo
software was used for analysis of the data.
Blocking and depleting CD8 Abs
CD8mAb (clone YTS169.4.2) was used to in vivo deplete CD8 T cells (25).
The mAbs used for tumor treatment were: anti-CTLA4 (200 mg), clone
9H10 and clone 9H9, courtesy of J. P. Allison (MD Anderson Cancer
Center); anti-PD1 (250 mg), clone RMP1-14; anti-CD30L (250 mg), clone
RM153; and anti-OX40L (250 mg), clone RM134L, courtesy of Hido
Yagita (Juntendo University School of Medicine, Tokyo, Japan); rat IgG
(Sigma-Aldrich) (250 mg) was used as a control. The mAbs were prepared
in sterile PBS and injected i.p. twice per week after 5 d of B16-F10 in-
jection (unless otherwise stated).
Liver function tests
A serum alanine aminotransferase (ALT) Beckman Coulter test kit (OSR 6107)
and aspartate aminotransferase (AST) were performed on the sera harvested at
sacrifice from experimental mice according to the manufacturer’s protocol and
analyzed using a Beckman Coulter AU400 analyzer by the Clinical Bio-
chemistry Unit, Women’s Hospital, Edgbaston, Birmingham, U.K.
Liver histology
Livers were excised and collected in cold RPMI 1640. The liver tissue was
fixed in 40% saline formalin (Adams), dehydrated, embedded in wax,
sectioned into 5-mm sections, and stained with H&E. The liver sections
were imaged by bright-field microscopy on a Leica DM6000 (Germany)
microscope, and areas of lymphocyte infiltration were identified and
counted at 310 and 320 magnifications.
Circulating serum autoantibody screening and titration
Blood was collected from mice by cardiac puncture according to UK
Home Office regulations. The blood samples were allowed to clot nat-
urally and then centrifuged at 13,000 rpm, 4˚C for 15 min. Isolated serum
was transferred into new tubes and stored at220˚C until use. Frozen sera
were thawed at room temperature and diluted 1:20 in 13 PBS. Com-
mercially prepared 10-spot rat tissue slides (NOVA Lite rat liver, kidney,
stomach) were removed from their bags and dried at room temperature
for 20 min. The slides were blocked with 10% goat serum (Sigma-
Aldrich) in 1% BSA/PBS (50 ml per spot) and incubated for 20 min at
room temperature in a dark humidified chamber. The diluted mice sera
were applied to the 10-spot slides and incubated as previously for 20
min. Slides were then washed in PBS for 5–10 min, excess fluid was
wiped from around spots, and 50 ml per spot of goat anti-mouse IgG
FITC was added and incubated for 20 min. The slides were washed and
antifade reagent was added; they were covered and then stored in the
dark at 4˚C until imaging. Positive, negative, and second-step controls
were also prepared. Tissues were imaged by fluorescence on a Leica
DM6000B (Germany) microscope, and data were interpreted using LAS
and Fiji software.
Statistical analysis
From previous experiments we know that when there is no overlap be-
tween experimental results in controls and test mice, groups of five mice
will achieve a statistical significance of p , 0.05 using nonparametric
statistics that do not assume a normal distribution. Based on preliminary
experiments, a power calculation was made that suggested an 80% power
to detect a significance of p , 0.05. Results from in vitro and in vivo
experiments were expressed as medians, with results from individual
mice shown as symbols. No mice were excluded from experimental
analysis. For experiments where mice were injected with various com-
binations of mAbs, the person who analyzed the results was blinded to
which Abs had been given to the different groups. We did not assume for
any group that they were normally distributed. Therefore, the Mann–
Whitney nonparametric test was used to analyze data using GraphPad
Prism software, and p , 0.05 was considered statistically significant.
FACS plots were analyzed using FlowJo v10 (Tree Star).
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Results
dKO Foxp3KO (tKO) mice resist B16-F10 melanoma tumor
growth but have increased infiltrates of PD1-expressing CD8
T cells
Tumor growth cannot be assessed in Foxp3KO mice, as they die of
lethal CD4-driven autoimmune disease by 4 wk of age. To assess
the impact of Treg deficiency, we therefore compared growth of the
melanoma line B16-F10 in WT C57BL/6 dKO (OX40 and CD30-
deficient) and tKO (dKO and Foxp3KO) mice. Mice were inoculated
with 5 3 105 melanoma cells in the flank, and tumor growth was
monitored using calipers. At day 21, all groups of mice were sac-
rificed, and tumors were excised. Compared to WT control mice
and dKO mice, tKO mice, which lack all Treg function, had sig-
nificantly reduced tumor growth (dKO, p , 0.023; WT, p , 0.003)
(Fig. 1B, Supplemental Fig. 1). Representative FACS data (Fig. 1A,
Supplemental Fig. 2A) and T cell infiltrates per gram of tumor are
shown in Fig. 1C–E, and T cell populations in tumor inguinal-
draining lymph nodes are shown in Supplemental Fig. 2B–D. The
normal CD4/CD8 T cell ratio seen in WT tumors was inverted in
tKO and dKO mice (Fig. 1A), supporting the role for OX40 and
CD30 signals in CD4 effector function and in agreement with the
abrogation of CD4 but not CD8 IFN-g expression reported previ-
ously for CD30KOOX40KO mice (23). However, CD8 tumor-
infiltrating cells showed significant expression of the inhibitory
receptors PD1 and CTLA4 (Fig. 1A, Supplemental Fig. 3A, 3B).
Enumeration of T cell subsets per gram of tumor showed a sig-
nificant increase in CD8 T cells (p , 0.009) in tKO versus WT
mice, with dKO mice showing intermediately increased infiltrates
of CD8 T cells (Fig. 1C). In contrast, there was a statistically
nonsignificant trend toward decreases in non-Treg CD4+ T cells in
dKO and tKO tumors compared with WT (Fig. 1D), as well as in
Treg numbers in dKO mice (Fig. 1E). Similar findings have been
reported for an OX40-deficient human (26). CD8 T cells infiltrating
tKO mice tumors showed similar expression of the activation
marker CD44, granzyme B, and IFN-g compared with WT and
dKO (Supplemental Fig. 3C–F). The inhibition of tumor growth in
tKO mice was substantially dependent on CD8 T cells, as CD8
depletion in tKO mice 12 d after injection with B16 melanoma cells
led to rapid growth of B16 melanoma compared with control-
injected mice (Fig. 2), as has been found by others (27, 28).
PD1 blockade acts synergistically in Foxp3KO dKO (tKO) mice,
and with WT mice injected with blocking mAbs to CTLA4, and
OX40L and CD30L, to prevent tumor growth
Because PD1 was expressed on tumor-infiltrating CD8 T cells, we
sought to understand whether addition of PD1-blocking mAbs
augmented the antitumor effect. WT, dKO, and tKO mice were
injected with B16 cells as previously, and after 3 d of injection the
mice were treated with mAbs twice per week for 3 wk. Tumor
growth was monitored weekly and all mice were sacrificed at day
22. Treatment with combined CTLA4 and PD1 Abs in dKO mice
virtually abrogated tumor growth and increased infiltrates of CD8
T cells as well as its effector functions compared with dKO mice
treated with control mAbs (p , 0.004) (Figs. 3A, 4A, 4C,
Supplemental Fig. 3E, 3F).
To tease apart the effect further, a cohort of 6- to 8-wk-old female
C57BL/6 mice was inoculated with tumor, and 5 d later, after
the tumors had become established, combinations of blocking
(CTLA4, PD1, OX40L, CD30L) or control mAbs were adminis-
tered twice weekly until tumors reached the tumor size limit
(12 mm in diameter) or day 42, at which point the remaining
FIGURE 1. Pattern of tumor growth and cellular infiltrates in WT, dKO, and tKO mice. Tumors were harvested 21 d after injection of 53 105 melanoma
B16-F10 cells in WT, dKO (OX40KOCD30KO), and tKO (OX40KOCD30KOFoxp3KO) mice and analyzed. (A) Typical flow cytometric analysis for each
group of mice, (B) tumor weight at harvest, (C) CD8 tumor infiltrates, (D) CD4 tumor infiltrates, and (E) Foxp3+ infiltrates are shown. Statistical analysis
was performed using a Mann–Whitney nonparametric test. Data are representative of three independent experiments, lines shows medians, and each symbol
represents one mouse (n = 16, 17, 15) in each group, respectively. *p , 0.05, **p , 0.01, ***p , 0.005.
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animals were sacrificed and analyzed. In mice that received control
mAbs, there was rapid growth of tumors (Fig. 3B, Supplemental
Fig. 1B). Injection of CTLA4-blocking Abs slowed down tumor
growth compared with controls, but they were not as effective as
PD1-blocking Abs (p , 0.03) or the combination of PD1 and
CTLA4 blockade (p , 0.003). CTLA4 and OX40L blockade was
more efficacious than CTLA4 blockade on its own (p, 0.03), and
PD1 and OX40L combined was equally efficacious as PD1 on its
own. Finally, the addition of OX40L- and CD30L-blocking Abs to
the PD1- and CTLA4-blocking combination was equally effica-
cious as combined CTLA4 and PD1 blockade. Analysis of infil-
trates in tumors revealed depletion of Foxp3+ Tregs in mice
injected with CTLA4- and PD1-blocking mAbs as previously
reported (13), with an increased proportion of CD8 T cells (Figs.
3C, 4A, 4D). In mice also injected with OX40L- and CD30L-
blocking mAbs, the proportion of CD8 T cells was further increased,
consistent with a primary role for OX40 and CD30 signals in
CD4 T cell survival (22).
Blocking Abs to CTLA4 and PD1, in combination with OX40L
and CD30L Abs, significantly attenuates concomitant CD4
autoimmunity
The above results indicated that addition of OX40L and CD30L
mAbs to combination CTLA4 and PD1 blockade did not interfere
with the CD8 antitumor immune response. We have previously
shown that OX40L and CD30L mAbs will block the liver immu-
nopathology in Foxp3KO mice (23). To test whether CTLA4 and
PD1 blockade caused significant off-target liver immunopathology,
we examined lymphocytic infiltrates in explanted livers of mice
treated with various combinations of control or blocking mAbs.
Compared to control-injected mice, all groups of mice had detect-
able lymphoid infiltrates, but these were much more extensive in
mice that received a combination of CTLA4 and PD1 blockade
(p, 0.02) (Fig. 5A–C). A significant finding in our studies was that
in all mice that received CTLA4 mAbs, intratumoral Tregs were
depleted, whereas Tregs in draining lymph node were retained
(Figs. 3C, 4A, 4D). This is consistent with previous findings with
these CTLA4-blocking Abs (13).
The addition of blocking Abs, either OX40L alone (p, 0.01) or
in combination with CD30L (p , 0.002), reduced liver infiltration
to ,5% of the level seen with CTLA4 and PD1 blockade, and this
correlated with liver function tests, which were normal with
OX40L and CD30L treatment and elevated in mice that received
just CTLA4 and PD1 (Fig. 5D, 5E). OX40 is the main driver of
pathology in Foxp3KO mice (23), and liver infiltrates in mice given
CTLA4, PD1, and OX40L were significantly less than in mice
treated with CTLA4 and PD1 blockade alone (p , 0.008); ALT
and AST liver enzymes were raised in this combination, but not
when CD30L-blocking mAbs were added, compatible with sig-
nificant synergy between OX40L and CD30L blockade in ame-
liorating off-target side effects.
Additionally, we looked at immunofluorescence staining of liver/
kidney and stomach for evidence of autoantibodies and saw reduced
mean fluorescence intensity in the group of mice that received
concurrent OX40L and CD30L blockade in combination with CTLA4
and PD1 mAbs (Supplemental Fig. 4A, 4B)
FIGURE 2. The suppression of tumor growth response in
tKO mice is substantially CD8-dependent. B16-F10 cells (5 3
105)were injected s.c. into the right flank of tKO mice. At day
12, mice were injected i.p. with either control or anti-CD8
mAbs. (A) Tumor volume at days 14, 21, and 26; line shows
means with error bars 6 SEM. (B) Tumor weight at excision;
each data point represents one mouse, and line shows medians.
(C) FACS analysis of tumor-draining lymph nodes (TdLN) and
tumor- infiltrating T cells, gated on CD3+ cells. (D) CD8 tu-
mor infiltrates. This experiment confirms previous observa-
tions by others that the antitumor response is CD8-dependent
(27). Data are representative of two independent experiments
(n = 6, 6) in each group. Statistical analysis was performed
using a Mann–Whitney nonparametric test. **p , 0.01, ***p
, 0.005.
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Final evidence of abrogation of autoimmunity was that vitiligo and
white hair at the injection site that were observed in three of seven
mice that received CTLA4 and PD1 mAbs (Supplemental Fig. 4C)
was not seen with mice that also received OX40L and CD30L
blockade (none of seven mice). In a murine model of vitiligo, CD4
T cells have been implicated as the main effector T cells (29).
Discussion
The above data suggest that a highly effectiveway to ameliorate the
CD4-driven toxicity associated with CTLA4 and PD1 blockade in
cancer treatment (8) would be to combine this therapy with blockade
of OX40 and CD30 signals, for cancers where CD8 T cells were the
main effectors of the anticancer response. In this study, as has been
reported elsewhere in mice (12–14) and humans (30), CTLA4 mAb
can deplete intratumoral Tregs but not those in the draining lymph
node, probably by Fc receptor–dependent mechanisms (12–14), in
addition to blocking CTLA4 interactions. Similar results causing
intratumoral Treg depletion have been reported with ipilimumab in
humans (30). Furthermore, mAbs to OX40 have also been shown to
also deplete intratumoral OX40+ Tregs (31), suggesting that intra-
tumoral Treg depletion can augment antitumor immune responses.
However, there is also evidence for efficacy with CTLA4-blocking
Abs of the IgG2 isotype that should not deplete intratumoral Tregs
(32), although there is some evidence that IgG2 mAbs can also
trigger myeloid but not NK-mediated Ab-dependent cellular cyto-
toxicity (33).
Although we found depletion of Tregs in our study, we cannot
exclude an additional role for CTLA4 blockade on tumor-infiltrating
T cells. In both CTLA4-deficient (10) and Foxp3-deficient mice (34),
autoimmunity is driven by CD4 effector pathology, and depletion
of Tregs in adult mice is associated with rapid onset of autoimmune
pathology (15). Although the autoimmunity seen in mice is less
severe with adult CTLA4 depletion (16, 17), haploinsufficiency
of CTLA4 has been associated with human autoimmunity, so it
is likely in humans that CTLA4 blockade also drives significant
autoimmunity (18, 19).
Additionally, OX40 is important for Treg function (35) (F.M.
Gaspal, D.R. Withers, M.G. Nawaf, F.M. McConnell, and P.J.L.
Lane, unpublished observations, particularly in combination with
CD30), so in theory OX40L and CD30L ligand mAbs would impair
Treg function even more than CTLA4 blockade on its own in situ-
ations where CTLA4 mAbs were nondepleting of intratumoral Tregs
(5), without compromising the antitumor CD8 response or causing
further off-target CD4-driven side effects.
OX40 signals are the main driver of autoimmunity in Foxp3KO
mice (23), and one potential worry is that blockade of OX40 signals
FIGURE 3. Harvested tumor weights (milligrams) and representative tumor-infiltrating lymphocytes in mice treated with control and blocking Abs. (A)
Day 22 harvested tumor weights (milligrams) after excision in WT, dKO, and tKO mice injected with blocking mAbs. Mice were injected with B16-F10 as
previously. Three days after melanoma inoculation, mice were injected with control or blocking Abs twice a week for 3 wk. The significance was calculated
using a Mann–Whitney nonparametric test. Data are representative of three independent experiments; the line shows medians in each group. *p, 0.05, **p
, 0.005. (B) Harvested tumor weights (milligrams) at day 42 or when tumor size reached 12 mm by caliper measurement (humane endpoint). Five days
after melanoma cells were injected, control or blocking mAbs were initiated twice a week until the experiment was terminated at day 42. Each data point
represents one mouse; line shows medians. Data are representative of three independent experiments. Statistical analysis was performed using a Mann–
Whitney nonparametric test. *p , 0.05, **p , 0.01. (C) Representative flow cytometry analysis of harvested WT control tumors, WT mice treated with
CTLA4 and PD1, and WT mice treated with CTLA4, PD1, OX40L, and CD30L mAbs.
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would compromise CD4 immune function, rendering patients sus-
ceptible to infection. In this regard it is reassuring that an OX40-
deficient patient did not suffer from infections with extracellular
bacterial infections, nor did they fail to control common herpesvirus
infections (27). Furthermore, we have data showing that dKO mice
vaccinated with the pneumococcal vaccine Prevenar were protected
from lethal challenge with live pneumococci (A.M. Mitchell, T.J.
Mitchell, and P.J.L. Lane, unpublished observations). This suggests
that basic protective immunity would not be compromised by OX40
blockade.
In human studies, there was a strong correlation between the dose of
PD1- and CTLA4-blocking Abs and anticancer efficacy, but further
escalation of dosagewas limited by dose-related toxicity (8). Our results
indicate that by blocking CD4-driven side effects, the block to dose
escalation would be removed. OX40L-blocking mAbs have been
studied in asthma trials (36) and although found to be ineffective in that
setting, they were shown to be safe. As far as we are aware, CD30L-
blocking mAbs have not been studied in human trials, although strat-
egies to block CD30L have been patented (patent WO2013163377 A1,
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013163377
&recNum=244&docAn=US2013038135&queryString=robotics&max
Rec=46977). By dissociating CD4-driven side effects from CD8-
mediated antitumor responses, we think combination therapy could
transform immunotherapy for cancer by bringing these treatments
to cancer patients much earlier in their diagnosis, and even as
upfront treatment rather than for late-stage metastatic disease.
FIGURE 4. Effect of CTLA4 and PD1 mAbs on tumor-infiltrated T cell populations in WT, dKO, and tKO mice. All tumors were harvested on day 22.
(A) Typical flow cytometric analysis for each group. (B) CD4+ tumor infiltrates, (C) CD8+ tumor infiltrates, and (D) Foxp3+ tumor infiltrates are shown.
Each dot represents one mouse; line shows medians. Statistical analysis was performed using a Mann–Whitney nonparametric test. Data are representative
of three independent experiments. *p , 0.05, **p , 0.01.
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